Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
Date:10/26/2011

l drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule wholly-owned by Nektar, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel proprietary topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
2. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
3. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
4. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
6. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
11. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... research analysis approaches are evolving across industry sectors ... are now examining better ways to engage with ... how consumers inform themselves and make critical purchasing ... by benchmarking firm, Best Practices, LLC, one area ...
(Date:7/11/2014)... Research and Markets has announced ... X-ray Film Industry Report 2014" report to their ... Global And Chinese Medical X-Ray Film Industry Report ... current state of the Global medical X-ray film industry ... report provides a basic overview of the industry including ...
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... and Company (NYSE: LLY ) will present data ... of the American Society of Clinical Oncology (ASCO) in Chicago, ... PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance ... cancer.  PARAMOUNT data will be included in the ASCO-sponsored press ...
... 16, 2011 PLC Systems Inc. (OTCBB: PLCSF), a ... financial results for the three- month period ended March ... operations, since PLC completed the sale of its transmyocardial ... quarter of 2011. Results from the TMR business for ...
Cached Medicine Technology:Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO 2PLC Systems Reports First Quarter 2011 Results 2PLC Systems Reports First Quarter 2011 Results 3PLC Systems Reports First Quarter 2011 Results 4PLC Systems Reports First Quarter 2011 Results 5PLC Systems Reports First Quarter 2011 Results 6PLC Systems Reports First Quarter 2011 Results 7
(Date:7/14/2014)... Institute (BTI) has entered into an agreement with ... to identify novel drug candidates for the detection ... BTI,s capabilities in novel antibody discovery and Roche,s ... opening up the possibility of improved treatment for ... , The collaboration makes use of BTI,s discovery ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Along with ... people with Alzheimer,s disease and other types of dementia, ... their quality of life, the researchers said. "These ... variety of benefits for people with dementia and their ... Lerner, of Case Western Reserve University and University Hospitals ...
(Date:7/14/2014)... physically active in middle age appears to help reduce ... dementia, suggest the findings from two new studies. ... various levels, especially in midlife, is beneficial for cognitive ... in an Alzheimer,s Association news release. "These are ... research is needed to determine the extent and nature ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... who enjoy mentally stimulating games may have bigger brains and ... The study looked at the connection between playing games such ... adults in their 50s and 60s. Researchers found that ... performed better on tests of memory and other mental functions. ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... symptoms of anxiety or depression, while children with problems ... forming relationships and being accepted by friends. However, it ... lead to the social problems, or vice versa. New ... contribute to anxiety and depression than the reverse. The ...
... intestine and large intestine led to lifesaving operation , , ... 63-year-old South Florida woman, was diagnosed last May with ... that had wrapped itself around her aorta and other ... the stomach, intestines and spleen. , Surgery wasn,t an ...
... and prescribe treatment for brain tumors by studying, under ... invasive biopsy or surgery. Now, researchers at UCSD School ... technology has the potential to non-invasively characterize tumors and ... forms of treatment, based on their specific molecular properties. ...
... March 24 Under contract with the,Air ... (AFCEE), ECC is,providing design-build services for a ... The 51,000-square-foot fitness center integrates contemporary,technologies, ... features include three NCAA-sized basketball courts, three,volleyball ...
... who have multiple first-degree relatives with colon cancer are ... recommended screening procedures, according to a report in the ... of the JAMA/Archives journals. , Family history increases risk ... the condition or if one immediate family member is ...
... encouraged in the trials process may improve overall care, ... Patients with heart attacks or other acute heart events ... in hospitals that take part in clinical trials, U.S. ... 174,000 patients with two types of heart conditions -- ...
Cached Medicine News:Health News:Youth's social problems contribute to anxiety and depression 2Health News:Woman's Abdominal Organs Removed in Unique Cancer Surgery 2Health News:MRI: A window to genetic properties of brain tumors 2Health News:ECC Builds Innovative, Green Fitness Center at Vandenberg Air Force Base (AFB) 2Health News:African Americans less likely than whites to get colonoscopy despite family history of colon cancer 2Health News:Patients Do Better at Hospitals With Clinical Trials 2
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... are used by hospitals, clinics and the ... health conditions. The majority of these products ... are offered in strip, cassette, and stick ... membrane tests are also available. All require ...
... The CALBIOTECH INC. (CBI) Prolactin ELISA ... of prolactin in human serum or plasma. ... chain polypeptide hormone with a molecular weight ... is based on a solid phase direct ...
... is a polypeptide hormone secreted in significant ... the placenta. Prolactin, in synergy with estrogen, ... initiation and maintenance of mammary gland growth ... prolactin may have effects on cell growth ...
Medicine Products: